Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - ARK Genomic Revolution ETF (BATS:ARKG)

Otsuka Pharmaceutical and Ionis Pharmaceuticals reported that their experimental drug, ulefnersen, met the primary endpoint in a late-stage study for FUS-ALS, a rare inherited form of ALS. The drug improved function and survival compared to placebo, with a favorable safety profile. The companies plan to discuss the results with the FDA and other health authorities for potential accelerated approval. Otsuka also launched a global early access program for eligible patients.

Ionis Pharmaceuticals (IONS) and Otsuka reported positive Phase 3 trial results for ulefnersen, an ALS treatment. The drug met its primary endpoint, showing significant improvement in function and survival. Ionis plans to discuss expedited FDA review. IONS shares rose 0.88% to $45.29.

Ionis Pharmaceuticals (IONS) and Otsuka Pharmaceutical announced that ulefnersen met its primary endpoint in a Phase 3 trial for FUS-ALS, showing significant improvement over placebo. The trial also met secondary endpoints, with most adverse events being mild or moderate. Otsuka plans to discuss results with regulators for potential expedited submission. Ionis received an upfront payment and is eligible for milestone payments and royalties under the licensing agreement.

JPMorgan lowered Ionis Pharmaceuticals' (IONS) price target to $70 from $76, citing a focus on Tryngolza launch and positive physician feedback on market opportunity. The firm maintains an Overweight rating.

The FDA approved Zanvastro, the first drug to treat Alexander disease, developed by Ionis Pharmaceuticals. Clinical trials showed it stabilized or improved motor function in patients. The drug targets the GFAP protein, reducing its production to prevent damage. Ionis will distribute it in the U.S. and license it globally through Recordati.

Ionis Pharmaceuticals (IONS) shares have fallen over 40% this year, despite analysts maintaining an average price target of $83.82. The company has six approved therapies, primarily for rare diseases, and is developing eight more in late-stage trials. Ionis reported a 40.7% revenue decline and a net loss in Q2, but analysts highlight its antisense oligonucleotide technology and potential for future growth.